Adrenal disorders and the paediatric brain: Pathophysiological considerations and clinical implications

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Salpietro, Vincenzo ^a,b   Polizzi, Agata ^c,d   Di Rosa, Gabriella ^b   Romeo, Anna Claudia ^b   Dipasquale, Valeria ^b   Morabito, Paolo ^b   Chirico, Valeria ^b   Arrigo, Teresa ^b   Ruggieri, Martino ^e  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MESSINA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; SUCCINATE DEHYDROGENASE;

ADDISON DISEASE; ADRENAL DISEASE; ADRENAL HYPERPLASIA; ADRENAL INSUFFICIENCY; ADRENAL MEDULLA DISEASE; ADRENOLEUKODYSTROPHY; ALLGROVE SYNDROME; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; BRAIN DAMAGE; CARBOHYDRATE METABOLISM; CARNEY COMPLEX; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL ADRENAL HYPOPLASIA; CONGENITAL DISORDER; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; ENZYME BLOOD LEVEL; FAMILIAL HYPERALDOSTERONISM; FAMILIAL PARAGANGLIOMA; GENETIC ASSOCIATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERALDOSTERONISM; HYPERCORTISOLISM; KEARNS SAYRE SYNDROME; LIPID METABOLISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEUROFIBROMATOSIS TYPE 1; NEUROIMAGING; NONHUMAN; PARAGANGLIOMA; PATHOPHYSIOLOGY; PEDIATRICS; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN METABOLISM; PSEUDOHYPERALDOSTERONISM; PSEUDOHYPOALDOSTERONISM; REVIEW; SMITH LEMLI OPITZ SYNDROME; VON HIPPEL LINDAU DISEASE; WHITE MATTER; X LINKED ADRENOLEUKODYSTROPHY;

EID: 84931291890     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/282489     Document Type: Review

References (121)

1. R. Roberts, W. Rodriguez, D. Murphy, and T. Crescenzi, "Pediatric drug labeling: improving the safety and efficacy of pediatric therapies," The Journal of the American Medical Association, Vol. 290, no. 7, pp. 905-911, 2003.
2. S. A. Bayer, J. Altman, R. J. Russo, and X. Zhang, "Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat," NeuroToxicology, Vol. 14, no. 1, pp. 83-144, 1993.
3. D. Rice and S. Barone Jr., "Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models," Environmental Health Perspectives, Vol. 108, supplement 3, pp. 511-533, 2000.
4. S. J. Barone, K. P. Das, T. L. Lassiter, and L. D. White, "Vulnerable processes of nervous system development: a review of markers and methods," NeuroToxicology, Vol. 21, no. 1-2, pp. 15-36, 2000.
5. S. N. Malaeb and B. S. Stonestreet, "Steroids and injury to the developing brain: net harm or net benefit?" Clinics in Perinatology, Vol. 41, no. 1, pp. 191-208, 2014.
6. L. S. Gorman, "The adrenal gland: common disease states and suspected new applications," Clinical Laboratory Science, Vol. 26, no. 2, pp. 118-125, 2013.
7. M. A. Magiakou, G. Mastorakos, E. H. Oldfield et al., "Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy," The New England Journal of Medicine, Vol. 331, no. 10, pp. 629-636, 1994.
8. C. A. Stratakis, "Cushing Syndrome in Pediatrics," Endocrinology and Metabolism Clinics of North America, Vol. 41, no. 4, pp. 793-803, 2012.
9. M. A. Magiakou and G. P. Chrousos, "Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies," Journal of Endocrinological Investigation, Vol. 25, no. 2, pp. 181-194, 2002.
10. T. E. Bertorini and A. Perez, "Neurologic complications of disorders of the adrenal glands," Handbook of Clinical Neurology, Vol. 120, pp. 749-771, 2014.
11. W. F. Kelly, "Psychiatric aspects of Cushing's syndrome," QJM, Vol. 89, no. 7, pp. 543-551, 1996.
12. P. T. Loosen, B. Chambliss, C. R. DeBold, R. Shelton, and D. N. Orth, "Psychiatric phenomenology in Cushings's disease," Pharmacopsychiatry, Vol. 25, no. 4, pp. 192-198, 1992.
13. D. J. Devoe, W. L. Miller, F. A. Conte et al., "Long-term outcome for children and adolescents following transphenoidal surgery for Cushing disease," The Journal of Clinical Endocrinology and Metabolism, Vol. 82, pp. 196-202, 1997.
14. J. P. Halper, "Corticosteroids and behavioural disturbances," in Principles of Corticosteroid Therapy, A. N. Lin and S. A. Paget, Eds., pp. 174-201, Arnold, London, UK, 2002.
15. M. Orchinik, S. S. Carroll, Y. H. Li, B. S. McEwen, and N. G. Weiland, "Heterogeneity of hippocampal GABAA receptors: regulation by corticosterone," Journal of Neuroscience, Vol. 21, no. 1, pp. 330-339, 2001.
16. F. A. Stuart, T. Y. Segal, and S. Keady, "Adverse psychological effects of corticosteroids in children and adolescents," Archives of Disease in Childhood, Vol. 90, no. 5, pp. 500-506, 2005.
17. I. Bourdeau, C. Bard, B. Nöel et al., "Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism," The Journal of Clinical Endocrinology & Metabolism, Vol. 87, no. 5, pp. 1949-1954, 2002.
18. E. Resmini, A. Santos, B. Gómez-Anson et al., "Verbal and visual memory performance and hippocampal volumes, measured by 3-tesla magnetic resonance imaging, in patients with Cushing's syndrome," Journal of Clinical Endocrinology and Metabolism, Vol. 97, no. 2, pp. 663-671, 2012.
19. D. P. Merke, J. N. Giedd, M. F. Keil et al., "Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome," Journal of Clinical Endocrinology and Metabolism, Vol. 90, no. 5, pp. 2531-2536, 2005.
20. J. Bentson, M. Reza, J. Winter, and G. Wilson, "Steroids and apparent cerebral atrophy on computed tomography scans," Journal of Computer Assisted Tomography, Vol. 2, no. 1, pp. 16-23, 1978.
21. R. Nass, L. Heier, T. Moshang et al., "Magnetic resonance imaging in the congenital adrenal hyperplasia population: Increased frequency of white-matter abnormalities and temporal lobe atrophy," Journal of Child Neurology, Vol. 12, no. 3, pp. 181-186, 1997.
22. Y. I. Sheline, P. W. Wang, M. H. Gado, J. G. Csernansky, and M. W. Vannier, "Hippocampal atrophy in recurrent major depression," Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, no. 9, pp. 3908-3913, 1996.
23. E. R. de Kloet, E. Vreugdenhil, M. S. Oitzl, and M. Jöels, "Brain corticosteroid receptor balance in health and disease," Endocrine Reviews, Vol. 19, no. 3, pp. 269-301, 1998.
24. R. M. Sapolsky, "The physiological relevance of glucocorticoid endangerment of the hippocampus," Annals of the New York Academy of Sciences, Vol. 746, pp. 294-307, 1994.
25. G. R. Criscuolo, "The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor," Yale Journal of Biology and Medicine, Vol. 66, no. 4, pp. 277-314, 1993.
26. J. Tjuvajev, H. Uehara, R. Desai et al., "Corticotropin-releasing factor decreases vasogenic brain edema," Cancer Research, Vol. 56, no. 6, pp. 1352-1360, 1996.
27. A. Shields, M. Thomson, V. Winter, J. Coalson, and S. Rees, "Repeated courses of antenatal corticosteroids have adverse effects on aspects of brain development in naturally delivered baboon infants," Pediatric Research, Vol. 71, no. 6, pp. 661-667, 2012.
28. I. Antonow-Schlorke, A. Helgert, C. Gey et al., "Adverse effects of antenatal glucocorticoids on cerebral myelination in sheep," Obstetrics and Gynecology, Vol. 113, no. 1, pp. 142-151, 2009.
29. O. M. Peltoniemi, M. A. Kari, A. Lano et al., "Two-year follow-up of a randomised trial with repeated antenatal betamethasone," Archives of Disease in Childhood: Fetal and Neonatal Edition, Vol. 94, no. 6, pp. F402-F406, 2009.
30. E. V. Asztalos, K. E. Murphy, M. E. Hannah et al., "Multiple courses of antenatal corticosteroids for preterm birth study: 2-Year outcomes," Pediatrics, Vol. 126, no. 5, pp. e1045-e1055, 2010.
31. C. A. Crowther, L. W. Doyle, R. R. Haslam, J. E. Hiller, J. E. Harding, and J. S. Robinson, "Outcomes at 2 years of age after repeat doses of antenatal corticosteroids," The New England Journal of Medicine, Vol. 357, no. 12, pp. 1179-1189, 2007.
32. R. J. Wapner, Y. Sorokin, L. Mele et al., "Long-term outcomes after repeat doses of antenatal corticosteroids," The New England Journal of Medicine, Vol. 357, no. 12, pp. 1190-1198, 2007.
33. A. Spinillo, F. Viazzo, R. Colleoni, A. Chiara, R. Maria Cerbo, and E. Fazzi, "Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity," The American Journal of Obstetrics and Gynecology, Vol. 191, no. 1, pp. 217-224, 2004.
34. N. P. French, R. Hagan, S. F. Evans, A. Mullan, and J. P. Newnham, "Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior," The American Journal of Obstetrics and Gynecology, Vol. 190, no. 3, pp. 588-595, 2004.
35. R. A. Brandão Neto and J. F. de Carvalho, "Diagnosis and classification of Addison's disease (autoimmune adrenalitis)," Autoimmunity Reviews, Vol. 13, no. 4-5, pp. 408-411, 2014.
36. E. Charmandari, N. C. Nicolaides, and G. P. Chrousos, "Adrenal insufficiency," The Lancet, Vol. 383, no. 9935, pp. 2152-2167, 2014.
37. S. Hsieh and P. C. White, "Presentation of primary adrenal insufficiency in childhood," Journal of Clinical Endocrinology and Metabolism, Vol. 96, no. 6, pp. E925-E928, 2011.
38. R. Perry, O. Kecha, J. Paquette, C. Huot, G. van Vliet, and C. Deal, "Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal," Journal of Clinical Endocrinology and Metabolism, Vol. 90, no. 6, pp. 3243-3250, 2005.
39. N. Condulis, G. Germain, N. Charest, S. Levy, and T. O. Carpenter, "Pseudotumor cerebri: a presenting manifestation of Addison's disease," Clinical Pediatrics, Vol. 36, no. 12, pp. 711-713, 1997.
40. G. Alexandrakis, V. Filatov, and T. Walsh, "Pseudotumor cerebri in a 12-year-old boy with Addison's disease," The American Journal of Ophthalmology, Vol. 116, no. 5, pp. 650-651, 1993.
41. I. Lasheen, S. A. R. Doi, and K. A. S. Al-Shoumer, "Gluco-corticoid replacement in panhypopituitarism complicated by myelinolysis a case report," Medical Principles and Practice, Vol. 14, no. 2, pp. 115-117, 2005.
42. J. Sajith, A. Ditchfield, and H. A. Katifi, "Extrapontine myelinol-ysis presenting as acute parkinsonism," BMC Neurology, Vol. 6, article 33, 2006.
43. C. Geenen, I. Tein, and R. M. Ehrlich, "Addison's disease presenting with cerebral edema," Canadian Journal of Neurological Sciences, Vol. 23, no. 2, pp. 141-144, 1996.
44. C. Lampl and K. Yazdi, "Central pontine myelinolysis," European Neurology, Vol. 47, no. 1, pp. 3-10, 2002.
45. S. Huq, M. Wong, H. Chan, and D. Crimmins, "Osmotic demyelination syndromes: central and extrapontine myelinoly-sis," Journal of Clinical Neuroscience, Vol. 14, no. 7, pp. 684-688, 2007.
46. R. H. Sterns, J. D. Cappuccio, S. M. Silver, and E. P. Cohen, "Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective," Journal of the American Society of Nephrology, Vol. 4, no. 8, pp. 1522-1530, 1994.
47. F. H. M. Cluitmans and A. E. Meinders, "Management of severe hyponatremia: rapid or slow correction?" The American Journal of Medicine, Vol. 88, no. 2, pp. 161-166, 1990.
48. L. F. Fried and P. M. Palevsky, "Hyponatremia and hyperna-tremia," Medical Clinics of North America, Vol. 81, no. 3, pp. 585-609, 1997.
49. A. Kaga, A. Saito-Hakoda, M. Uematsu et al., "Brain white matter abnormality in a newborn infant with congenital adrenal hyperplasia," Clinical Pediatric Endocrinology, Vol. 22, no. 4, pp. 77-81, 2013.
50. V. Salpietro, A. Polizzi, L. F. Bertè et al., "Idiopathic intracranial hypertension: a unifying neuroendocrine hypothesis through the adrenal-brain axis," Neuroendocrinology Letters, Vol. 33, no. 6, pp. 569-573, 2012.
51. S. T. Jarrel, E. H. Oldfield, and R. R. Lonser, "Chapter 6, von hippel-lindau disease," in Neurocutaneous Disorders: Phakomatosis and Hamartoneoplastic Syndromes, M. Ruggieri, I. Pascual-Castroviejo, and C. Di Rocco, Eds., Chapter 6, pp. 229-248, Springer, Wien, New York, NY, USA, 2008.
52. E. Kebebew, J. E. Gosnell, and E. Reiff, "Multiple Endocrine Neoplasia type 2B," in Neurocutaneous Disorders: Phakomatosis and Hamartoneoplastic Syndromes, M. Ruggieri, I. Pascual-Castroviejo, and C. di Rocco, Eds., chapter 46, pp. 695-701, Springer, New York, NY, USA, 2008.
53. D. P. Merke and S. R. Bornstein, "Congenital adrenal hyperpla-sia," The Lancet, Vol. 365, no. 9477, pp. 2125-2136, 2005.
54. D. P. Merke, J. D. Fields, M. F. Keil, A. C. Vaituzis, G. P. Chrousos, and J. N. Giedd, "Children with classic congenital adrenal hyperplasia have decreased amygdala volume: potential prenatal and postnatal hormonal effects," Journal of Clinical Endocrinology and Metabolism, Vol. 88, no. 4, pp. 1760-1765, 2003.
55. M. Winfeld, P. Patel, B. Shah, R. Nass, and S. Milla, "Early occurrence of cerebral white matter abnormality detected in a neonate with salt-wasting congenital adrenal hyperplasia," Journal of Pediatric Endocrinology and Metabolism, Vol. 26, no. 1-2, pp. 13-17, 2013.
56. R. Bergamaschi, C. Livieri, C. Uggetti et al., "Brain white matter impairment in congenital adrenal hyperplasia," Archives of Neurology, Vol. 63, no. 3, pp. 413-416, 2006.
57. S. Lee, M. Sanefuji, K. Watanabe et al., "Clinical and MRI characteristics of acute encephalopathy in congenital adrenal hyperplasia," Journal of the Neurological Sciences, Vol. 306, no. 1-2, pp. 91-93, 2011.
58. M. F. Mnif, M. Kamoun, F. Mnif et al., "Brain magnetic resonance imaging findings in adult patients with congenital adrenal hyperplasia: increased frequency of white matter impairment and temporal lobe structures dysgenesis," Indian Journal of Endocrinology and Metabolism, Vol. 17, no. 1, pp. 121-127, 2013.
59. F. S. Maheu, D. P. Merke, E. A. Schroth et al., "Steroid abnormalities and the developing brain: declarative memory for emotionally arousing and neutral material in children with congenital adrenal hyperplasia," Psychoneuroendocrinology, Vol. 33, no. 2, pp. 238-245, 2008.
60. L. Mazzone, S. C. Mueller, F. Maheu, C. Vanryzin, D. P. Merke, and M. Ernst, "Emotional memory in early steroid abnormalities: an fMRI study of adolescents with congenital adrenal hyperplasia," Developmental Neuropsychology, Vol. 36, no. 4, pp. 473-492, 2011.
61. L. Bezman and H. W. Moser, "Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.," American journal of medical genetics, Vol. 76, no. 5, pp. 415-419, 1998.
62. M. Engelen, S. Kemp, M. de Visser et al., "X-linked adrenoleu-kodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management," Orphanet Journal of Rare Diseases, Vol. 7, no. 1, article 51, 2012.
63. M. Kaga, W. Furushima, M. Inagaki, and M. Nakamura, "Early neuropsychological signs of childhood adrenoleukodystrophy (ALD)," Brain and Development, Vol. 31, no. 7, pp. 558-561, 2009.
64. P. Aubourg, "X-linked adrenoleukodystrophy," Annales d'Endocrinologie, Vol. 68, no. 6, pp. 403-411, 2007.
65. N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae et al., "Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy," Science, Vol. 326, no. 5954, pp. 818-823, 2009.
66. M. Valenzise, A. Meloni, C. Betterle et al., "Chronic inflamma-tory demyelinating polyneuropathy as a possible novel component of autoimmune poly-endocrine-candidiasis-ectodermal dystrophy," European Journal of Pediatrics, Vol. 168, no. 2, pp. 237-240, 2009.
67. J. R. Berger, A. Weaver, J. Greenlee, and G. E. Wahlen, "Neurologic consequences of autoimmune polyglandular syndrome type 1," Neurology, Vol. 70, no. 23, pp. 2248-2251, 2008.
68. V. Ramanjam, S. Delport, and J. M. Wilmshurst, "The diagnostic difficulties of complex glycerol kinase deficiency," Journal of Child Neurology, Vol. 25, no. 10, pp. 1269-1271, 2010.
69. M. F. Messina, M. Autunno, K. Koehler et al., "Upper and lower motor neuron involvement as presenting manifestation of Triple a syndrome," Journal of Endocrinological Investigation, Vol. 32, no. 5, pp. 482-483, 2009.
70. D. B. Grant, N. D. Barnes, M. Dumic et al., "Neurological and adrenal dysfunction in the adrenal insufficiency/ alacrima/achalasia (3A) syndrome," Archives of Disease in Childhood, Vol. 68, no. 6, pp. 779-782, 1993.
71. C. E. Fardella and L. Mosso, "Primary aldosteronism," Clinical Laboratory, Vol. 48, no. 3-4, pp. 181-190, 2002.
72. P. R. Larsen, H. M. Kronenberg, and S. Melmed, Eds., The Adrenal Cortex, and Endocrine Hypertension, Williams Text Book of Endocrinology, Saunders, Philadelphia, Pa, USA, 2003.
73. B. Spoto, G. Furlo, A. Gervasi et al., "Familial hyperaldostero-nism," G Ital Nefrol, Vol. 21, pp. 139-143, 2004.
74. H. W. Seyberth and K. P. Schlingmann, "Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects," Pediatric Nephrology, Vol. 26, no. 10, pp. 1789-1802, 2011.
75. A. W. Root, "Disorders of aldosterone synthesis, secretion, and cellular function," Current Opinion in Pediatrics, Vol. 26, no. 4, pp. 480-486, 2014.
76. U. A. Hawkins, E. P. Gomez-Sanchez, C. M. Gomez-Sanchez, and C. E. Gomez-Sanchez, "The ubiquitous mineralocorticoid receptor: clinical implications," Current Hypertension Reports, Vol. 14, no. 6, pp. 573-580, 2012.
77. V. Salpietro and M. Ruggieri, "Pseudotumor cerebri pathophys-iology: the likely role of aldosterone," Headache, Vol. 54, no. 7, article 1229, 2014.
78. F. Mantero, M. Palermo, M. D. Petrelli, R. Tedde, P. M. Stewart, and C. H. L. Shackleton, "Apparent mineralocorticoid excess: type I and type II," Steroids, Vol. 61, no. 4, pp. 193-196, 1996.
79. S. Dave-Sharma, R. C. Wilson, M. D. Harbison et al., "Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess," The Journal of Clinical Endocrinology & Metabolism, Vol. 83, no. 7, pp. 2244-2254, 1998.
80. S. B. Magill, "Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders," Comprehensive Physiology, Vol. 4, no. 3, pp. 1083-1119, 2014.
81. N. B. B. Knops, L. A. Monnens, J. W. Lenders, and E. N. Levtchenko, "Apparent mineralocorticoid excess: time of manifestation and complications despite treatment," Pediatrics, Vol. 127, no. 6, pp. e1610-e1614, 2011.
82. F. G. Riepe, "Pseudohypoaldosteronism," Endocrine Development, Vol. 24, pp. 86-95, 2013.
83. G. Jain, S. Ong, and D. G. Warnock, "Genetic disorders of potassium homeostasis," Seminars in Nephrology, Vol. 33, no. 3, pp. 300-309, 2013.
84. R. R. Borrego Domínguez, A. Imaz Roncero, J. López-Herce Cid, and C. Seriñá Ramírez, "Severe hypernatremia: survival without neurologic sequelae," Anales de Pediatrí a, Vol. 58, no. 4, pp. 376-380, 2003.
85. J. K. Healy, "Pseudohypoaldosteronism type II: history, arguments, answers, and still some questions," Hypertension, Vol. 63, no. 4, pp. 648-654, 2014.
86. J. A. McCormick and D. H. Ellison, "The WNKs: atypical protein kinases with pleiotropic actions," Physiological Reviews, Vol. 91, no. 1, pp. 177-219, 2011.
87. R. D. Gordon, "Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate," Hypertension, Vol. 8, no. 2, pp. 93-102, 1986.
88. M. Shekarabi, N. Girard, J.-B. Rivière et al., "Mutations in the nervous system-specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II," Journal of Clinical Investigation, Vol. 118, no. 7, pp. 2496-2505, 2008.
89. D. L. Rogers, "A review of pediatric idiopathic intracranial hypertension," Pediatric Clinics of North America, Vol. 61, no. 3, pp. 579-590, 2014.
90. P. K. Newman, M. Snow, and P. Hudgson, "Benign intracranial hypertension and Cushing's disease," British Medical Journal, Vol. 281, no. 6233, article 113, 1980.
91. A. Levine, N. Watemberg, H. Hager, Y. Bujanover, A. Ballin, and T. Lerman-Sagie, "Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease," Journal of Child Neurology, Vol. 16, no. 6, pp. 458-461, 2001.
92. L. E. Andrews, G. T. Liu, and M. W. Ko, "Idiopathic intracranial hypertension and obesity," Hormone Research in Pædiatrics, Vol. 81, no. 4, pp. 217-225, 2014.
93. M. K. Birmingham, M. Sar, and W. E. Stumpff, "Localization of aldosterone and corticosterone in the central nervous system, assessed by quantitative autoradiography," Neurochemical Research, Vol. 9, no. 3, pp. 333-350, 1984.
94. V. Salpietro, R. Chimenz, T. Arrigo, and M. Ruggieri, "Pediatric idiopathic intracranial hypertension and extreme childhood obesity: a role for weight gain," Journal of Pediatrics, Vol. 162, article 1084, no. 5, 2013.
95. V. Salpietro, K. Mankad, M. Kinali et al., "Pediatric idio-pathic intracranial hypertension and the underlying endocrine-metabolic dysfunction: a pilot study," Journal of Pediatric Endocrinology and Metabolism, Vol. 27, no. 1-2, pp. 107-115, 2014.
96. M. Usman Khan, H. Khalid, V. Salpietro, and K. T. Weber, "Idiopathic intracranial hypertension associated with either primary or secondary aldosteronism," The American Journal of the Medical Sciences, Vol. 346, no. 3, pp. 194-198, 2013.
97. V. Salpietro, M. Ruggieri, F. Sancetta et al., "New insights on the relationship between pseudotumor cerebri and secondary hyperaldosteronism in children," Journal of Hypertension, Vol. 30, no. 3, pp. 629-630, 2012.
98. A. J. Sinclair, E. A. Walker, M. A. Burdon et al., "Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11β-HSD1 and intracranial pressure regulation?" The Journal of Clinical Endocrinology and Metabolism, Vol. 95, no. 12, pp. 5348-5356, 2010.
99. A. Kushida and H. Tamura, "Retinoic acids induce neurosteroid biosynthesis in human glial GI-1 cells via the induction of steroidogenic genes," Journal of Biochemistry, Vol. 146, no. 6, pp. 917-923, 2009.
100. V. Chirico, S. Cannavò, A. Lacquaniti et al., "Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction," Clinical Endocrinology, Vol. 79, no. 4, pp. 537-544, 2013.
101. T. Arrigo, V. Chirico, V. Salpietro et al., "High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children," European Journal of Endocrinology, Vol. 168, no. 4, pp. 631-638, 2013.
102. J. S. Barton, P. C. Hindmarsh, M. A. Preece, and C. G. D. Brooke, "Blood pressure and the renin-angiotensin-aldosterone system in children receiving recombinant human growth hormone," Clinical Endocrinology, Vol. 38, no. 3, pp. 245-251, 1993.
103. M. Lampit, T. Nave, and Z. Hochberg, "Water and sodium retention during short-term administration of growth hormone to short normal children," Hormone Research, Vol. 50, no. 2, pp. 83-88, 1998.
104. R. Batra and A. Sinclair, "Sinclair A Idiopathic intracranial hypertension; research progress and emerging themes," Journal of Neurology, Vol. 261, no. 3, pp. 451-360, 2014.
105. A. F. Rakototiana, A. C. Ramorasata, H. N. Rakoto-Ratsimba, F. A. Hunald, T. Rajaobelison, and H. Y. H. Rantomalala, "Pheochromocytoma revealed by stroke in a child," Archives de Pediatrie, Vol. 15, no. 10, pp. 1531-1534, 2008.
106. H. V. Luiz, T. N. da Silva, B. D. Pereira et al., "Malignant paraganglioma presenting with hemorrhagic stroke in a child," Pediatrics, Vol. 132, no. 6, pp. e1709-e1714, 2013.
107. S. Abourazzak, S. Atmani, L. E. Arqam et al., "Cerebral ischaemic stroke and bilateral pheochromocytoma," BMJ Case Reports, Vol. 2010, 2010.
108. B. V. Jones, J. C. Egelhoff, and R. J. Patterson, "Hypertensive encephalopathy in children," The American Journal of Neuroradiology, Vol. 18, no. 1, pp. 101-106, 1997.
109. B. J. Kelley, S. Samples, and R. Kunkel, "PRES following administration of DHE in a patient with unsuspected pheochro-mocytoma," Headache, Vol. 48, no. 8, pp. 1237-1239, 2008.
110. K. Mankad, E. Hoey, and K. S. Yap, "Reversible leukoen-cephalopathy syndrome," The American Journal of Emergency Medicine, Vol. 28, no. 3, pp. 386.e3-386.e5, 2010.
111. A. Serter, A. Alkan, A. Aralasmak, and E. Kocakoc, "Severe posterior reversible encephalopathy in pheochromocytoma: importance of susceptibility-weighted MRI," Korean Journal of Radiology, Vol. 14, no. 5, pp. 849-853, 2013.
112. M. Sharma, J. C. Kupferman, Y. Brosgol et al., "The effects of hypertension on the paediatric brain: a justifiable concern," The Lancet Neurology, Vol. 9, no. 9, pp. 933-940, 2010.
113. B.-J. Petri, C. H. J. van Eijck, W. W. de Herder, A. Wagner, and R. R. de Krijger, "Phaeochromocytomas and sympathetic paragangliomas," British Journal of Surgery, Vol. 96, no. 12, pp. 1381-1392, 2009.
114. R. Martins and M. J. Bugalho, "Paragangliomas/pheochro-mocytomas: clinically oriented genetic testing," International Journal of Endocrinology, Vol. 2014, Article ID 794187, 14 pages, 2014.
115. M. Peczkowska and A. Januszewicz, "Multiple endocrine neo-plasia type 2," Familial Cancer, Vol. 4, no. 1, pp. 25-36, 2005.
116. M. Ruggieri, V. Pavone, D. de Luca, A. Franzò, A. Tiné, and L. Pavone, "Congenital bone malformations in patients with neu-rofibromatosis type 1 (Nf1)," Journal of Pediatric Orthopaedics, Vol. 19, no. 3, pp. 301-305, 1999.
117. M. Ruggieri, "The different forms of neurofibromatosis," Child's Nervous System, Vol. 15, no. 6-7, pp. 295-308, 1999.
118. M. M. Walther, J. Herring, E. Enquist, H. R. Keiser, W. M. Linehan, and W. Marston Linehan, "Von Recklinghausen's disease and pheochromocytomas," Journal of Urology, Vol. 162, no. 5, pp. 1582-1586, 1999.
119. L. Zinnamosca, L. Petramala, D. Cotesta et al., "Neurofibro-matosis type 1 (NF1) and pheochromocytoma: Prevalence, clinical and cardiovascular aspects," Archives of Dermatological Research, Vol. 303, no. 5, pp. 317-325, 2011.
120. M. Ruggieri, A. Polizzi, V. Salpietro et al., "Spinal neurofibro-matosis with central nervous system involvement in a set of twin girls and a boy: further expansion of the phenotype," Neuropediatrics, Vol. 44, no. 5, pp. 239-244, 2013.
121. M. Ruggieri, A. L. Gabriele, A. Polizzi et al., "Natural history of neurofibromatosis type 2 with onset before the age of 1 year," Neurogenetics, Vol. 14, no. 2, pp. 89-98, 2013.